Sebastian Kobold

The paper evaluates multi-laboratory studies to identify promising treatments by assessing effect sizes and experimental rigor across different medical fields.

The paper identifies suppressive atypical memory B cells in AML that are amplified by CAR T cell interactions and shows that targeting both B cells and AML blasts can overcome this suppression.

This paper validates a multicenter preclinical strategy for CAR T cells, demonstrating its feasibility in confirming CCR8 overexpression benefits across multiple centers.

This study develops bispecific antibodies targeting IGLV3-21R110 to selectively kill high-risk CLL cells while sparing healthy B cells and stem cells.

This study reviews and meta-analyzes CAR-T cell therapy trials and preclinical models to assess their predictive value, finding that preclinical models poorly predict outcomes when using their own features.

This paper develops AI-designed protein binders for cancer cell surface proteins, showing their effectiveness in detection and targeting through experimental validation and benchmarking of structure prediction models.

This study develops CAR T cells targeting a specific mutation in CLL to selectively kill cancer cells while sparing healthy B cells.